Diagnostic Instruments

Worldwide Market for Cancer Diagnostics, 4th Edition, The now available at ReportsandReports

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.
These changes and more are addressed in Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:
• Histology/Cytology
• Immunoassays
• Flow Cytometry
• Rapid Tests
• Molecular Assays
• Tissue Arrays
• Circulating Tumor Cells
• Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:
• Immunoassay Lab Based Cancer Test Sales
• Pap Smear Testing Volumes
• World Cancer Statistics
• POC Tests
• DNA Reagents for Cancer Testing
• CTC Testing Markets
• Biochip Innovations
• New Companies with Novel Approaches
• "Laggard" Companies Who Have Not Met Expectations
• Major Protein and Molecular Markers Used in Tissue Staining
• Biomarkers Under Investigation
• Acquisitions and Mergers
• Status of PGx Testing
• Microarray Markets in Clinical Labs
• Lists of Vendors and Major Products
• Unmet Needs of the Marketplace

This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH As well as tests for specific cancers:
• Bladder Cancer
• Breast Cancer
• Cervical Cancer
• Colon Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer

This latest edition of Kalorama Information's study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:
• Tests for specific cancers, and
• Cancer tests in specific IVD segments
This allows the reader to match his or her own situation to the market at large.

Table OF Contents
CHAPTER ONE: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Test Segments
Geographic Distribution
Market Trends
Death Rates
Revolutionary Therapeutics
Physician Factor
Consumer Lobby
Price

CHAPTER TWO: Introduction
Background
Pharmacogenomics
Test Service Commercialization
Cancer - Diagnosis and Therapy Management
Point of View

CHAPTER THREE: Market Trends In The Commercialization Of Cancer Diagnostics
Background
Demographics of Cancer, a Global Phenomenon
Cancer Testing in the World:
Screening and Government Supported Programs
United States of America
International
Europe
Mexico
China
India
Reimbursement and Commercialization of Novel Tests
Test Services - Route for Cancer Innovation
Table 3-3
Regulatory requirements of new products
Strategic Alliances and Partnerships
Personalized Medicine Advances
Gene Patents and Test Commercialization

CHAPTER FOUR: Technological Trends
Background
Biomarker Revolution
The promise of Personalized Medicine
Miniaturization and Multiplexed Biological Assays
The emergence of non-invasive tools
New Technologies Applied To Cancer Diagnostics
Overview
New Platforms
Mass Spectrometry
Chromosome Analysis
Next-Generation Sequencing
RNA - Ribonucleic Acid
The In Vitro/In Vivo Mix

CHAPTER FIVE: Market Analysis
Background
World Regional Segments of the Market for Cancer Diagnostics
Companies and Products
Has Screening Lost its Allure?
Cancer Specific Tests
Bladder Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer

CHAPTER SIX: Cancer Tests in IVD Segments (Segment Analysis)
Cancer Diagnostics and IVD Markets
The Market For Cancer Tests In Clinical Chemistry
The Market For Immunoassay Cancer Tests, Lab & Rapid
Point-of-care
The Market for Cancer Tests in Histology / Cytology
Traditional Tissue Stains
Pap Smear and HPV Testing
IHC/ISH
The Market for Tissue Microarrays
The Market For Cancer Tests in Flow Cytometry
The Market for Circulating Tumor Cells in Cancer Diagnostics
The Market For Cancer Molecular Assays
The Market For Cancer Tests in Pharmacodiagnostics
The market for Biochips and Arrays in Cancer Diagnostics
The Commercial Outlook for Cancer Diagnostics

CHAPTER SEVEN: Conclusions
Conclusions and Strategic Implications
Conclusion 1
Implication:
Conclusion 2
Implication:
Conclusion 4
Implication
Conclusion 5
Implication:
Conclusion 6:
Unmet Market Needs
Unmet Need #1
Unmet Need #2
Unmet Need #3

CHAPTER EIGHT: The Top Tier of IVD Companies and their investment in cancer diagnostics
Abbott Diagnostics
Molecular Histology
Molecular Diagnostics
Immunoassays
Beckman Coulter Inc
FOB
Flow Cytometry
Becton, Dickinson and Company (BD)
Histology
bioMerieux Inc
Bio-Rad Laboratories Inc
Dako A/S
Fujirebio Diagnostics, Inc
Gen-Probe Inc
Hologic, Inc
Histology
HPV
Inverness Medical Innovations
Ortho Clinical Diagnostics
QIAGEN N.V
Roche Diagnostics Indianapolis, IN www.roche.com Recent Revenue History ($ million)
Histology
Immunoassays
PCR
Research
Siemens Medical Solutions Diagnostics
Molecular
In Vivo
Sysmex Corporation

CHAPTER NINE: The Status Quo in Cancer Diagnostics
AdnaGen AG
Agendia BV
AMDL Diagnostics, Inc. (ADI)
American Diagnostica Inc
Aperio Technologies, Inc
Asuragen, Inc
AviaraDx
Binding Site (The) Ltd
BioCurex Inc
BioGenex Laboratories, Inc
BioImagene
Bio-Reference Laboratories, Inc
Biotage AB
bioTheranostics
BioView Ltd
Celera Diagnostics
China Medical Technologies, Inc
Cisbio Bioassays
Clarient Inc. (formerly ChromaVision)
Clinical Data, Inc
CytoCore, Inc
DxS Ltd
Epigenomics AG
Genetix Applied Imaging
Genomic Health, Inc
Genzyme Genetics
Health Discovery Corporation
HistoRx, Inc
Ikonisys, Inc
InterGenetics Inc
Ipsogen SA
Lab21 Healthcare
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies
Monogram Biosciences, Inc
mtm laboratories AG
Myriad Genetics, Inc
Nanosphere, Inc
OncoVista Innovative Therapies, Inc
Pathwork Diagnostics
Precision Therapeutics
Prometheus Laboratories Inc
Quest Diagnostics
Response Genetics, Inc
Rosetta Genomics Ltd
Sequenom
Transgenomic Inc
Veridex, LLC
Vermillion Inc
Zila, Inc

CHAPTER TEN: New Entrants And Novel Product Developers
20/20 GeneSystems, Inc
454 Life Sciences Corporation
Acrometrix Corporation (Life Tech.)
Acupath Laboratories, Inc
Advalytix
Affymetrix, Inc
Allegro Diagnostics
Althea Technologies, Inc
Amorfix Life Sciences Ltd
Arbor Vita Corporation
ArcticDx Inc
Arrayit Diagnostics Inc
AVEO Pharmaceuticals, Inc
Axela, Inc
Baypoint Biosystems, Inc
Biodesix, Inc
Biologix Diagnostics, LLC
BioMarker Strategies, LLC
Biomoda
BioMosaics
BioProspecting NB, Inc. (BPNBI)
BioServe
Biosystems International SAS (BSI)
BioTrove, Inc
Cambridge Research & Instrumentation, Inc. (CRi)
Cangen Biotechnologies, Inc
Caris Diagnostics
Castle Biosciences Inc
Celerus Diagnostics
Cell Biosciences
CeMines, Inc
Cepheid
ChromoCure Inc
Chronix Biomedical Inc
Clinical Genomics Pty Ltd
CombiMatrix Molecular Diagnostics (CMDX)
Comprehensive Cancer Cell (CCC) Diagnostics Inc
Compugen Ltd
Correlogic Systems, Inc
CS-Keys, Inc
deCode Genetics Inc. ---
DiaGenic ASA
DiagnoCure --
Diagnoplex
Diagnostic Biosystems Company
DNA Direct, Inc
DexTerity Diagnostics
EDP Biotech Corporation
Epistem Plc
Exact Sciences Corp
Exiqon A/S
ExonHit Therapeutics
Exosome Diagnostics Inc
Expression Pathology Inc
Falcon Genomics, Inc
FASgen Diagnostics, LLC
Fluxion Biosciences
Foligo Therapeutics, Inc
Gastrocor
Genelex Corporation
GeneNews Limited
Genoptix
iKaryos Diagnostics
Illumina
Inostics GmbH
InteRNA Technologies B.V
Intrinsic Bioprobes Inc
Invirion Diagnostics, LLC
InVivoScribe Technologies
Iris BioTechnologies Inc
IRIS International, Inc
MabCure Inc
MacroArray Technologies, LLC
MagArray Inc
Martell Biosystems, Inc
Med BioGene, Inc. (MBI)
Medical Prognosis Institute
Metabolon, Inc
Miraculins Inc
MolecularMD Corp
Neogenix Oncology, Inc
NextGen Sciences
Nuvera Biosciences
Olink AB
Oncimmune LLC
OncoMethylome Sciences S.A
On-Q-ity
Orion Genomics
Oxford BioTherapeutics
Pacific Edge Biotechnology Ltd. (PEB)
Photocure ASA
Power3 Medical Products, Inc
Prediction Sciences
Predictive Biosciences
PrognosDx Health, Inc
Provista Life Sciences LLC
Rubicon Genomics, Inc
Rules-Based Medicine, Inc. (RBM)
Saladax Biomedical, Inc. (SBI)
SensiGen LLC
Sienna Cancer Diagnostics
Signature Genomic Laboratories, LLC
Singulex Inc
Skyline Diagnostics B.V
Source MDx
Soar BioDynamics, Ltd
Strategic Diagnostics Inc
Synergenz Bioscience Ltd
Targeted Molecular Diagnostics (TMD)
Theranostics Health (TH)
TrimGen Corporation
TrovaGene, Inc
Vitatex Inc
WaferGen Biosystems, Inc
Xceed Molecular (formerly MetriGenix Corporation)
Zetiq Technologies Ltd

About the Author

Worldwide Market for Cancer Diagnostics, 4th Edition, The now Available on ReportsandReports. ReportsandReports, comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites.

Yes To Dental Capacities

In 1973 the Skylab space travels began marking the start of manned space flights into earth orbit and during this time the astronauts relied on different modern dental equipment as they proceeded with their journey. Because of the military dentists at the National Aeronautics and Space Administration or NASA the in flight medical support system or IMSS during the Skylab space travels accommodated a relevant dental component. Three man crews were sent into space from 28 to 56 days during the Skylab program and on all of the three flights launched during this period modern dental equipment was utilized. As a person looking for sydney orthodontist you should visit that site.

 

Dealing with problems that could be treated on an outpatient basis was the philosophy for the kind of service that the dental equipment aimed to provide as one of the military dentists said. On the other hand the equipment still did not act simply as a buddy kit or a do it yourself kit. Each of the three man crews involved in space travels for 28 days had a one percent risk for dental problems and ideas on possible treatments resulted from such a statistic. No room is given for any ineffectiveness during work and when there are cases of pulpitis or periodontal abscess the knowledge pertaining to dental risks allowed for early preparations.

 

On the average there is a five percent risk that less serious concerns including fractured restorations may be experienced. There are a lot of things that come with the IMSS dental equipment this article will discuss including tools from forceps to a Gigli saw as well as restorative material, syringes, and anesthetic. Conditions in outer space proved to be a detrimental factor to the kind of restoration material that will work effectively for NASA but the Air Force den corps were able to formulate the material which met in flight specifications. Handling or mixing the material can be accomplished in zero gravity.

 

NASA did not only conduct a series of intensive training programs for the flight crews but also conducted a series of tests to ensure that there will be no flaws in the dental equipment. Basically the purpose of conducting the training programs was for the flight crews to learn implementing different procedures not exceeding the skill level needed for tooth removal. Illustrations of the oral cavity from personal radiographs, diagnosis information, as well as procedural guidelines will be integrated into a dental manual that will be placed on the space vehicle. When you would like to get more information on sydney braces check out this site.

 

There will always be a dentist available in mission control equipped with all the materials that may be needed by the astronauts from oral casts to files containing narrative summaries of all dental procedures done to astronauts since 1966. Every space mission requires an extensive use of space to ground conversation and in this case procedures cannot simply be done without the approval of an on ground dental officer.

 

Not everyone who is concerned about this program supports training astronauts to perform dental procedures on themselves while in space as legitimate dentists still prove to be the wiser option. It is also important to consider that a space mission can easily be threatened should one of the crew members experience much pain and in the case of the Skylab missions a huge financial loss may not be easily accepted. To avoid any unexpected problems the dental procedures will no longer act as the primary approach should dental problems arise.

Vauxhall corsa fault finding?

A local garage has my Vauxhall Corsa in for fault fixing, and they are having trouble trying to 'not rip me off' They say the fault isn;t in my exhaust system, nor the fuel pump, but the engine will only tick over, if I try to derive it the engine will not rev high enough for me to get out of first gear, but splutters to a halt and cuts out.
They also say the catalytic converter is in good working order too, but the exhaust is quite hot at the outlet tail pipe at the rear of my car. the RAC towed my car to this garage, after telling me that the problem was simple to resolve as it was in something to do with the fuel temperature, as the reading on his diagnostic instrument computer in his van was telling him that the unit on my car was faulty, Why can't this garage sort out the problem, any answers please from my friendly Yahoo engineers??

This garage can't find your fault as they are using multi use diagnostic equipment. It sounds as though your car has gone into limp home mode. If the engine management light has come on then it will register as a fault in the ecu. If there is no light on then it sounds like an EGR valve that is causing the problem. Best bet is to take it to a Vauxhall dealer and ask them to put it on Tech2 as this is Vauxhall diagnostic equipment. Try hear for more advice. Better to register with the site.

http://www.cavweb-forums.co.uk/forumdisplay.php?f=83

FDA Clears Gen-Probe's HPV Test - Analyst Blog (Zacks)

Gen-Probe has secured the FDA approval for its APTIMA HPV assay.

Zacks

Riester Jungingen - medical diagnostic instruments